Musculoskeletal Diseases Commons^™

Fibromyalgia Syndrome: A Pathoneurological Basis Of Disease, Alex D. Hamilton

Senior Honors Papers

Fibromyalgia (also known as fibromyalgia syndrome, or FMS) is a condition which causes its victims to suffer a wide range of symptoms, most notably chronic musculoskeletal pain. Although the causes of fibromyalgia remain unknown, recent advances help elucidate the underlying pathophysiologies of this condition, and show that it is likely not a musculoskeletal condition, but rather a pathoneurological condition.

Alterations In Skeletal Muscle Strength And Mitochondrial Function Induced By Aging And Exercise, Justin Crane

Open Access Dissertations and Theses

Introduction: Mitochondria are important organelles for skeletal muscle function. Mitochondria are susceptible to many forms of stress that alters their morphology, energy generation and reactive oxygen species (ROS) production, which collectively promote degeneration and dysfunction in skeletal muscle. These processes are implicated in many health disorders, particularly in the aging process itself. Exercise is well established to increase muscle mitochondrial content and thus may attenuate several aspects of mitochondrial deterioration. Methods: Both human and animal models of mitochondrial stress (aging, ROS) were utilized in order to determine their effects on mitochondrial and muscle function. Additionally, exercise training was used in ...

Long-Term Safety Of Pegloticase In Chronic Gout Refractory To Conventional Treatment, Michael A. Becker, Herbert S. B. Baraf, Robert A. Yood, Aileen Dillon, Janitzia Vazquez-Mellado, Faith D. Ottery, Dinesh Khanna, John S. Sundy

Meyers Primary Care Institute Publications and Presentations

OBJECTIVE: To evaluate the long-term safety (up to 3 years) of treatment with pegloticase in patients with refractory chronic gout.

METHODS: This open-label extension (OLE) study was conducted at 46 sites in the USA, Canada and Mexico. Patients completing either of two replicate randomised placebo-controlled 6-month trials received pegloticase 8 mg every 2 weeks (biweekly) or every 4 weeks (monthly). Safety was evaluated as the primary outcome, with special interest in gout flares and infusion-related reactions (IRs). Secondary outcomes included urate-lowering and clinical efficacy.

RESULTS: Patients (n=149) received a mean+/-SD of 28+/-18 pegloticase infusions and were followed ...

Patients' Knowledge And Beliefs Concerning Gout And Its Treatment: A Population Based Study, Leslie R. Harrold, Kathleen M. Mazor, Daniel J. Peterson, Nausheen Naz, Cassandra L. Firneno, Robert A. Yood

Meyers Primary Care Institute Publications and Presentations

BACKGROUND: For patients to effectively manage gout, they need to be aware of the impact of diet, alcohol use, and medications on their condition. We sought to examine patients' knowledge and beliefs concerning gout and its treatment in order to identify barriers to optimal patient self-management.

METHODS: We identified patients (>/=18 years of age) cared for in the setting of a multispecialty group practice with documentation of at least one health care encounter associated with a gout diagnosis during the period 2008-2009 (n = 1346). Patients were sent a questionnaire assessing knowledge with regard to gout, beliefs about prescription medications used ...

Characterization Of Cardiomyopathy In A Mouse Model Of Duchenne Muscular Dystrophy (Dmd) Using Echocardiography, Dce-Ct, And Pet-Fdg, Seyed Hamed Moazami

Electronic Thesis and Dissertation Repository

Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disease that is the result of a loss of functional dystrophin, which causes cardiomyocyte fibrosis and death, leading to cardiomyopathy. In this thesis, I have utilized dynamic contrast-enhanced computed tomography (DCE-CT), positron emission tomography-fluorodeoxyglucose (PET-FDG), echocardiography, and traditional histology to longitudinally assess disease progression and degree of cardiomyopathy in a murine model of DMD (mdx:utrn-/-). No significant changes were observed in the blood flow, blood volume, or cardiac volume measured via DCE-CT, nor in standard uptake value (SUV) of glucose as measured by PET-FDG in the left myocardium between and ...